Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Authors:
Open Access
- 14 June 2021
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 71 (2) , 251-265
Abstract
Introduction: The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incompletely understood.Methods: We performed comparative mRNA expression profiling of 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung ADC focused on immune gene expression. The presence and levels of tumor infiltration lymphocytes (TILs) as well as fourteen specific immune cell populations were estimated from the gene expression profiles.Results: While total TILs were not lower in ALK-positive and EGFR-positive tumors compared to ALK/EGFR-negative tumors, specific immunosuppressive characteristics were detected in both subgroups: In ALK-positive tumors, regulatory T cells were significantly higher compared to EGFR-positive (fold change: FC = 1.9,p = 0.0013) and ALK/EGFR-negative tumors (FC = 2.1,p = 0.00047). In EGFR-positive tumors, cytotoxic cells were significantly lower compared to ALK-positive (FC = − 1.7,p = 0.016) and to ALK/EGFR-negative tumors (FC = − 2.1,p = 2.0E-05). A total number of 289 genes, 40 part of cytokine–cytokine receptor signaling, were differentially expressed between the three subgroups. Among the latter, five genes were differently expressed in both ALK-positive and EGFR-positive tumors, while twelve genes showed differential expression solely in ALK-positive tumors and eleven genes solely in EGFR-positive tumors.Conclusion: Targeted gene expression profiling is a promising tool to read out tumor microenvironment characteristics from routine diagnostic lung cancer biopsies. Significant immune reactivity including specific immunosuppressive characteristics in ALK- and EGFR-positive lung ADC, but not a total absence of immune infiltration supports further clinical evaluation of immune-modulators as partners of ICB in such tumors.Keywords
Funding Information
- Deutsche Zentrum für Lungenforschung
- Roche
- Universitätsklinikum Heidelberg
This publication has 60 references indexed in Scilit:
- Tumor-Infiltrating Regulatory T Cells Inhibit Endogenous Cytotoxic T Cell Responses to Lung AdenocarcinomaThe Journal of Immunology, 2013
- CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3Cancer Cell, 2011
- The prognostic value of intraepithelial and stromal innate immune system cells in non‐small cell lung carcinomaHistopathology, 2009
- Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical OutcomeCancer Research, 2009
- Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survivalEuropean Respiratory Journal, 2008
- Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung CancerClinical Cancer Research, 2008
- OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the TumorCancer Research, 2008
- TH1 cells control themselves by producing interleukin-10Nature Reviews Immunology, 2007
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- Immunosuppressive networks in the tumour environment and their therapeutic relevanceNature Reviews Cancer, 2005